May 31, 2018 08:24 AM EDT
R&D

Madri­gal shares soar on promis­ing PhII NASH da­ta, stok­ing hopes for a new con­tender

John Carroll

Editor & Founder

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Phar­ma in­vestors brush off Trump’s ‘most fa­vored na­tion’ plan as stocks rise

Watch Post-Hoc Live: Trump's 'most fa­vored na­tion' plan to cut drug prices

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

Bris­tol My­ers CEO says Amer­i­ca’s bio­phar­ma pole po­si­tion is not guar­an­teed

Bay­er starts 2025 by cut­ting 2,000 jobs as it homes in on year-end re­haul tar­get

A service from the Financial Times